Knowledge Center
Article / Jul 27, 2015
Hovione and Invion sign development agreement for first inhaled non-steroidal anti-inflammatory for asthma
Source:
Manufacturing Chemist, 27 July 2015
Portuguese API manufacturer Hovione has agreed with Invion to progress the development of inhaled INV104 (zafirlukast) as a potential new treatment for asthma.
Hovione and the Australian drug developer will collaborate to develop the proprietary novel technology – a dry powder formulation of the compound INV104 (zafirlukast) delivered by Hovione’s inhaler.
Related links
Also in the Knowledge Center
/ Jan 01, 2012
Manufacture of a triiodinated contrast agent via a new compound of (S)-5-(2-acetoxypropanamido)-2,4,6-triiodoisophthalic acid
Read more
Scientific Article
/ Jan 01, 2012
Method for the production of fluoromethyl - esters of androstan- 17 - beta - carboxylic acids
Read more
Scientific Article
Scientific Article